Medela legt zich al sinds meer dan 60 jaar toe op de ondersteuning en bevordering van borstvoeding en lactatie, met behulp van wetenschappelijk onderzoek, educatie en innovatieve oplossingen. Om deze focus te versterken en in lijn te blijven met de Internationale Gedragscode voor het op de markt brengen van vervangingsmiddelen voor moedermelk van de Wereldgezondheidsorganisatie, voert Medela een belangrijke wijziging door in het portfolio.
Uiterlijk op 1 juli 2025 stopt Medela met de verkoop van zuigflessen en spenen. De productie en inkoop zijn inmiddels gestaakt; de productie van fopspenen werd al in november 2024 beëindigd. Deze veranderingen onderstrepen onze voortdurende toewijding om borstvoeding en lactatieondersteuning voorop te stellen.
Deze beslissing, genomen onder leiding van voorzitter Michael Larsson en CEO Thomas Golücke, en volledig gesteund door de Raad van Bestuur en het Group Management, bevestigt opnieuw de doelstelling van Medela om borstvoeding wereldwijd te bevorderen. Door producten uit het assortiment te verwijderen die mogelijk onder de WHO-code vallen, versterkt Medela de samenwerking met de onderzoeks-, borstvoedings- en lactatiegemeenschap.
We blijven ons inzetten voor de ondersteuning van borstvoedende gezinnen wereldwijd, zodat elke baby toegang heeft tot moedermelk – de best mogelijke voeding voor een gezonde start in het leven. Dit doel blijven we nastreven met duidelijkheid, zorg en toewijding. Als onderdeel van deze toewijding ondersteunen we moeders en gezinnen met innovatieve oplossingen voor borstkolven en borstverzorging. Tegelijkertijd pakken we belangrijke uitdagingen aan, zoals het opbouwen van een volledige melkproductie en het bevorderen van succesvolle rechtstreekse borstvoeding.
Wij ondersteunen moeders bij het maken van weloverwogen keuzes over de voeding van hun baby – ongeacht hoe hun reis eruitziet. Hoewel we geen zuigflessen en spenen meer zullen aanbieden, erkennen we dat er diverse opties op de markt beschikbaar zijn die inspelen op verschillende behoeften en voorkeuren. Medela blijft medische en gespecialiseerde voedingsoplossingen aanbieden, zoals aanvullende voedingssystemen, speciale voedingssystemen, Soft Cups, Baby Cup-feeders, FingerFeeders en enterale voedingsoplossingen, om ervoor te zorgen dat baby's met voedingsproblemen toegang hebben tot de beste producten.
Medela’s commitment to aligning with the aim of the WHO Code has been long-standing. The milestones below outline the steps we have taken to evolve our practices and portfolio, reflecting our consistent support for breastfeeding.
There is no international body that certifies companies as compliant with the WHO International Code. However, according to UNICEF guidance, companies are responsible for demonstrating their own alignment through their policies and actions. The following provides a transparent record of Medela’s journey and the steps taken since 2020.
Medela began a full review of its marketing practices in collaboration with lactation professionals and associations. New Marketing Guidelines were introduced to ensure Medela did not promote its products in ways that could be interpreted as detracting from breastfeeding.
These guidelines removed idealizing language, images and claims, such as “similar to breastfeeding,” “natural,” and established clear standards for product presentation. Feeding bottles were only shown in the context of breast milk feeding, with supporting elements emphasizing the breastfeeding relationship, like a breast pump in the background when feeding bottles were present.
Additionally, an internal and external whistleblower mechanism was established to enable reporting of concerns related to Medela’s or that of its distributors’ marketing practices via marketingguidelines@medela.com
These steps intended to reinforce the purpose of our feeding bottles as a means of supporting breastfeeding relationships and helping mothers during periods of separation.
Ongoing engagement with IBCLCs, professional associations, and other lactation stakeholders across multiple regions helped better language, educational content, and how products were presented.
Marketing Guidelines were further strengthened to ensure products under the scope of the Code were no longer promoted. Product imagery, text and references that could be interpreted as idealizing bottle-feeding practices were removed from Medela webpages and partner platforms where needed.
All product descriptions, Instructions for Use, and packaging of feeding bottles were revised to ensure factual, non-idealizing language, including appropriate warnings about the introduction of bottle feeding.
Alongside the existing reporting channel, an anonymous internal reporting system was introduced to support Medela's employees in raising non-compliance concerns.
A new website was launched, removing all imagery of products under the scope of the Code except where required for Instructions for Use. A formal, comprehensive WHO International Code Policy was issued in alignment with all WHO Code and WHA resolutions.
Further to this, Sales and Marketing teams received training on Medela’s obligations under the Code, appropriate language, and acceptable use of imagery.
Medela publicly announced its decision to discontinue all feeding bottles and teats worldwide. This step was taken to provide clarity on Medela’s position for clinicians, families, and advocacy groups and to eliminate ambiguity regarding product categories within the scope of the WHO Code.
A global stop‑sale of all feeding bottles and teats came into effect, with regional phase-outs managing remaining legacy stock.
Pacifiers were also voluntarily discontinued, although not within the scope of the Code, to further reduce potential ambiguity and strengthen Medela’s commitment to breastfeeding.
With these changes, Medela exited all product categories covered under the WHO Code and continues to uphold its commitment to protect and promote breastfeeding.
An annual review of web and educational materials was conducted to ensure full consistency and removal of references to products under the scope of the Code.
Medela expanded engagement with the global lactation community through listening sessions and ongoing dialogue with IBCLCs and healthcare professionals. Medical Affairs, academic partners, and research leaders committed to quarterly updates on human milk science. Annual transparency reporting and external advisory review processes were established.

Aligning with the WHO Code: Strengthening Medela’s Commitment to Breastfeeding
This recorded webinar features Medela’s CEO and Medical Affairs team informing on the company’s full alignment with the World Health Organization’s International Code of Marketing of Breast-Milk Substitutes and the company’s commitment to advancing breastfeeding support and education globally.
Aired on July 22, 2025
Medela no longer has products that fall under the scope of the WHO International Code of Marketing of Breast milk Substitutes (WHO Code). Since 2020, we have taken structural steps to align with the aim of the Code, including revising marketing practices and permanently discontinuing feeding bottles and teats in 2025.
UNICEF guidance confirms that there is no global certification system for Code compliance and that companies are responsible for demonstrating their own adherence.
Feeding bottles and teats fall within the scope of the WHO Code. Permanently discontinuing these products removes any ambiguity around Medela’s position, reinforces our alignment with the aim of the Code, and strengthens our commitment to protecting and promoting breastfeeding.
No. Medela’s milk storage containers are an integral part of Medela’s breast pump systems, designed to enable effective milk collection and to support the pump in achieving and maintaining appropriate suction. The system is developed and validated as a whole, and its performance relies on these components being used together.
Medela does not manufacture or provide teats, and the containers are developed and positioned solely for milk collection and storage as part of the pump system, not as feeding bottles.
Breastfeeding support tools such as Supplemental Nursing Systems (SNS) and nipple shields are clinically important, evidence-based interventions used to manage specific lactation and feeding challenges and preserve human milk feeding. They support conditions such as ineffective latch, low milk supply, and the need for supplementation or induced lactation.
Special needs feeders are used for specific medical indications, such as infants with anatomical or neurological challenges who cannot safely breastfeed. They are not intended to replace breastfeeding but support medically necessary feeding for specific vulnerable populations. Medela will follow WHO’s guidance related to this product.
Some professional organizations have introduced their own internal transition or waiting periods before re‑engaging with companies that were previously not fully aligned with the Code. These are organization‑specific policies, not requirements or recommendations from WHO or UNICEF.
While we respect that some organizations have chosen to apply defined timelines, we believe the most meaningful bases for engagement is an objective, evidence‑based assessment of current practices and sustained compliance. Medela remains fully committed to the irreversible steps we have taken, including the discontinuation of all feeding bottles and teats, and to ongoing, open dialogue with the professional community.
There is limited precedent in this area. The only other known comparable case involved a company that was recognized as aligned with the WHO Code after independent lactation advocates assessed its practices and confirmed alignment.
Medela supports breastfeeding and human milk feeding through a sustained commitment to science, clinical care, and education, focused on the needs of families and healthcare providers, particularly in situations where lactation is most at risk such as maternal–infant separation. Our work centers on advancing human milk research, developing evidence‑based breast pump technologies and breast care solutions, and supporting hospital and NICU lactation practices globally to help establish and maintain milk supply. We also invest in clinician education to equip care teams with the knowledge and tools needed to improve outcomes for mothers and infants.
This commitment is reinforced by Medela’s ownership structure: Medela is owned by the Family Larsson‑Rosenquist Foundation, a charitable organization regulated under Swiss law. The Foundation independently commits the profits to advancing scientific and medical research, its translation into practice, and other projects related to human lactation. Together, these efforts reflect a consistent and long‑standing focus on promoting, protecting, and supporting breastfeeding through science, clinical partnership, and responsible practices.
Medela maintains internal and external processes for reporting Code related concerns. These can be submitted to marketingguidelines@medela.com Any identified issues are reviewed and corrected as part of our ongoing quality and compliance processes.